hydroxyurea has been researched along with Leukocytosis in 41 studies
Leukocytosis: A transient increase in the number of leukocytes in a body fluid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperleukocytosis occurs in 15-20% of all newly diagnosed acute myeloid leukemia patients and requires emergent treatment with leukapheresis or hydroxyurea when accompanied by signs or symptoms of leukostasis." | 7.91 | Dose-related mucositis with hydroxyurea for cytoreduction in acute myeloid leukemia. ( Auten, JJ; Clark, SM; Trepte, ML; van Deventer, HW, 2019) |
| "The effect of hydroxyurea on blood viscosity was studied in 10 patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and hyperleukocytosis (white blood cell counts over 200 x 10(9)/l)." | 7.68 | Effect of hydroxyurea on blood viscosity in chronic myelogenous leukemia with hyperleukocytosis. ( Bhat, SV; Rao, S; Sharma, K, 1991) |
| "The effect of hydroxyurea in 35 patients with chronic granulocytic leukemia (CGL), who either had entered an accelerated phase of the disease or had experienced excessive myelosuppression following alkylating agents, was studied." | 7.65 | Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. ( Cannellos, GP; Schwartz, JH, 1975) |
| " After two patients had a rapid increase in WBC counts and clinical signs reminiscent of the 'ATRA syndrome' seen in acute promyelocytic leukemia, with fatal outcome in one of them, it was decided to add hydroxyurea (HY) to ATRA to patients with high WBC at inclusion or during ATRA treatment, and no more cases of ATRA syndrome were seen." | 5.08 | All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. ( Cambier, N; Chomienne, C; Fenaux, P; Guerci, A; Menot, ML; Wattel, E, 1996) |
| "A 48-year-old woman was admitted with chronic myelogenous leukemia in November, 1996 and was treated with hydroxyurea (HU), because of marked leukocytosis; WBC 404,000/microliter." | 4.80 | [Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea]. ( Fujimaki, K; Fujisawa, S; Hattori, M; Kodama, F; Maruta, A; Mohri, H; Motomura, S; Okubo, T; Sakai, R; Takahashi, N; Tomita, N, 1998) |
| "Hyperleukocytosis occurs in 15-20% of all newly diagnosed acute myeloid leukemia patients and requires emergent treatment with leukapheresis or hydroxyurea when accompanied by signs or symptoms of leukostasis." | 3.91 | Dose-related mucositis with hydroxyurea for cytoreduction in acute myeloid leukemia. ( Auten, JJ; Clark, SM; Trepte, ML; van Deventer, HW, 2019) |
| "Imatinib mesylate has been reported to produce positive results in atypical chronic myeloproliferative disorders (CMD) with chromosomal translocations that disrupt the platelet-derived growth factor receptor beta gene (PDGFRB)." | 3.72 | Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. ( Bastie, JN; Castaigne, S; Cross, NC; Garcia, I; Mahon, FX; Terré, C, 2004) |
| "The effect of hydroxyurea on blood viscosity was studied in 10 patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and hyperleukocytosis (white blood cell counts over 200 x 10(9)/l)." | 3.68 | Effect of hydroxyurea on blood viscosity in chronic myelogenous leukemia with hyperleukocytosis. ( Bhat, SV; Rao, S; Sharma, K, 1991) |
| "The effect of hydroxyurea in 35 patients with chronic granulocytic leukemia (CGL), who either had entered an accelerated phase of the disease or had experienced excessive myelosuppression following alkylating agents, was studied." | 3.65 | Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. ( Cannellos, GP; Schwartz, JH, 1975) |
| "Leukostasis is a life-threatening complication of high concentrations of circulating leukemic cells, most often myeloblasts." | 2.82 | Hyperleukocytosis and leukostasis in acute and chronic leukemias. ( Macaron, W; Sargsyan, Z; Short, NJ, 2022) |
| "In idiopathic myelofibrosis (IMF) PDGF is considered to be one of the growth factors responsible for the development of bone marrow fibrosis." | 2.71 | Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. ( Birgens, H; Bjerrum, OW; Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Ralfkiaer, E; Therkildsen, MH, 2003) |
| "Hyperleukocytosis is defined as a white blood cell count greater than 100." | 2.58 | The management of hyperleukocytosis in 2017: Do we still need leukapheresis? ( Korkmaz, S, 2018) |
| "Hyperleukocytosis can induce leukostasis, which can lead to vascular obstructions (usually in the lungs and central nervous system), tumor lysis syndrome, and disseminated intravascular coagulation." | 2.52 | How we approach a patient with symptoms of leukostasis requiring emergent leukocytapheresis. ( Pham, HP; Schwartz, J, 2015) |
| "Hyperleukocytosis, arbitrarily defined in acute leukemia as a white blood cell count greater than 100,000/mL, often is associated with increased morbidity and mortality in patients with leukemic processes." | 2.48 | Hyperleukocytosis, leukostasis and leukapheresis: practice management. ( Becker, J; Ganzel, C; Lazarus, HM; Mintz, PD; Rowe, JM, 2012) |
| "These data suggest a role of GM-CSF in leukocytosis of SCD." | 1.34 | Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease. ( Conran, N; Costa, FF; Ikuta, T; Saad, ST, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (14.63) | 18.7374 |
| 1990's | 7 (17.07) | 18.2507 |
| 2000's | 10 (24.39) | 29.6817 |
| 2010's | 14 (34.15) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Macaron, W | 1 |
| Sargsyan, Z | 1 |
| Short, NJ | 1 |
| Cerrano, M | 1 |
| Seegers, V | 1 |
| Raffoux, E | 2 |
| Rabian, F | 1 |
| Sébert, M | 1 |
| Itzykson, R | 1 |
| Lemiale, V | 2 |
| Adès, L | 1 |
| Boissel, N | 2 |
| Dombret, H | 2 |
| Azoulay, E | 2 |
| Lengliné, E | 2 |
| Bewersdorf, JP | 1 |
| Giri, S | 1 |
| Tallman, MS | 1 |
| Zeidan, AM | 1 |
| Stahl, M | 1 |
| Diao, S | 1 |
| Nichols, ED | 1 |
| DiNardo, C | 1 |
| Konopleva, M | 1 |
| Ning, J | 1 |
| Qiao, W | 1 |
| Maiti, A | 1 |
| DiPippo, AJ | 1 |
| Bertolini, F | 1 |
| Cassisa, A | 1 |
| Miggiano, MC | 1 |
| Gasparin, P | 1 |
| Trepte, ML | 1 |
| Auten, JJ | 1 |
| Clark, SM | 1 |
| van Deventer, HW | 1 |
| Korkmaz, S | 1 |
| Bertoli, S | 1 |
| Tavitian, S | 1 |
| Picard, M | 1 |
| Huguet, F | 1 |
| Vergez, F | 1 |
| Delabesse, E | 1 |
| Sarry, A | 1 |
| Bérard, E | 1 |
| Récher, C | 1 |
| Park, SH | 1 |
| Chi, HS | 1 |
| Cho, YU | 1 |
| Jang, S | 1 |
| Park, CJ | 1 |
| Kim, DY | 1 |
| Lee, JH | 1 |
| Lee, KH | 1 |
| Scott, KM | 1 |
| Gardner, FP | 1 |
| Eidelman, BH | 1 |
| Rivera, CE | 1 |
| Menke, DM | 1 |
| Barrett, KM | 1 |
| Kuo, KH | 1 |
| Callum, JL | 1 |
| Panzarella, T | 1 |
| Jacks, LM | 1 |
| Brandwein, J | 1 |
| Crump, M | 1 |
| Curtis, JE | 1 |
| Gupta, V | 1 |
| Lipton, JH | 1 |
| Minden, MD | 1 |
| Sher, GD | 1 |
| Schimmer, AD | 1 |
| Schuh, AC | 1 |
| Yee, KW | 1 |
| Keating, A | 1 |
| Messner, HA | 1 |
| Pham, HP | 1 |
| Schwartz, J | 1 |
| Mamez, AC | 1 |
| Chevret, S | 1 |
| Canet, E | 1 |
| Schlemmer, B | 1 |
| Badawy, SM | 1 |
| Caramazza, D | 1 |
| Caracciolo, C | 1 |
| Barone, R | 1 |
| Malato, A | 1 |
| Saccullo, G | 1 |
| Cigna, V | 1 |
| Berretta, S | 1 |
| Schinocca, L | 1 |
| Quintini, G | 1 |
| Abbadessa, V | 1 |
| Di Raimondo, F | 1 |
| Siragusa, S | 1 |
| Bajwa, AA | 1 |
| Usman, F | 1 |
| Wolfson, D | 1 |
| Laos, LF | 1 |
| Cury, JD | 1 |
| Martínez-Trillos, A | 1 |
| Gaya, A | 1 |
| Maffioli, M | 1 |
| Arellano-Rodrigo, E | 2 |
| Calvo, X | 1 |
| Díaz-Beyá, M | 1 |
| Cervantes, F | 2 |
| Yannaki, E | 1 |
| Papayannopoulou, T | 1 |
| Jonlin, E | 1 |
| Zervou, F | 1 |
| Karponi, G | 1 |
| Xagorari, A | 1 |
| Becker, P | 1 |
| Psatha, N | 1 |
| Batsis, I | 1 |
| Kaloyannidis, P | 1 |
| Tahynopoulou, V | 1 |
| Constantinou, V | 1 |
| Bouinta, A | 1 |
| Kotta, K | 1 |
| Athanassiadou, A | 1 |
| Anagnostopoulos, A | 1 |
| Fassas, A | 1 |
| Stamatoyannopoulos, G | 1 |
| Ganzel, C | 1 |
| Becker, J | 1 |
| Mintz, PD | 1 |
| Lazarus, HM | 1 |
| Rowe, JM | 1 |
| Binder, WD | 1 |
| Brown, DF | 1 |
| Nadel, ES | 1 |
| Au, WY | 1 |
| Ma, SK | 1 |
| Wan, TS | 1 |
| Wang, EP | 1 |
| Lau, TC | 1 |
| Kwong, YL | 1 |
| Hasselbalch, HC | 1 |
| Bjerrum, OW | 1 |
| Jensen, BA | 1 |
| Clausen, NT | 1 |
| Hansen, PB | 1 |
| Birgens, H | 1 |
| Therkildsen, MH | 1 |
| Ralfkiaer, E | 1 |
| Bastie, JN | 1 |
| Garcia, I | 1 |
| Terré, C | 1 |
| Cross, NC | 1 |
| Mahon, FX | 1 |
| Castaigne, S | 1 |
| Rudolph, G | 1 |
| Haritoglou, C | 1 |
| Schmid, I | 1 |
| Hochhaus, F | 1 |
| Kampik, A | 1 |
| Conran, N | 1 |
| Saad, ST | 1 |
| Costa, FF | 1 |
| Ikuta, T | 1 |
| Bhave, AA | 1 |
| Rao, RG | 1 |
| Patil, GT | 1 |
| Berger, R | 1 |
| Hillion, J | 1 |
| Janvier, D | 1 |
| Chen, Z | 1 |
| Bussel, A | 1 |
| Hwang, WL | 1 |
| Gau, JP | 1 |
| Chen, MC | 1 |
| Young, JH | 1 |
| Cambier, N | 1 |
| Wattel, E | 1 |
| Menot, ML | 1 |
| Guerci, A | 1 |
| Chomienne, C | 1 |
| Fenaux, P | 1 |
| Motomura, S | 1 |
| Sakai, R | 1 |
| Tomita, N | 1 |
| Fujimaki, K | 1 |
| Hattori, M | 1 |
| Fujisawa, S | 1 |
| Mohri, H | 1 |
| Takahashi, N | 1 |
| Maruta, A | 1 |
| Kodama, F | 1 |
| Okubo, T | 1 |
| Hernández-Boluda, JC | 1 |
| Carreras, E | 1 |
| Marín, P | 1 |
| Rovira, M | 1 |
| Solé, F | 1 |
| Lloveras, E | 1 |
| Espinet, B | 1 |
| Ocejo, A | 1 |
| Montserrat, E | 1 |
| Hur, M | 1 |
| Song, EY | 1 |
| Kang, SH | 1 |
| Shin, DH | 1 |
| Kim, JY | 1 |
| Park, SS | 1 |
| Cho, HI | 1 |
| Berg, J | 1 |
| Vincent, PC | 1 |
| Gunz, FW | 1 |
| Schwartz, JH | 1 |
| Cannellos, GP | 1 |
| Balducci, L | 1 |
| Hardy, CL | 1 |
| Sharma, K | 1 |
| Rao, S | 1 |
| Bhat, SV | 1 |
| Snyder, AB | 1 |
| Barone, JG | 1 |
| DiGiacomo, JC | 1 |
| Barone, JE | 1 |
| Schwarzenberg, L | 1 |
| Mathé, G | 1 |
| Pouillart, P | 1 |
| Weiner, R | 1 |
| Locour, J | 1 |
| Genin, J | 1 |
| Schneider, M | 1 |
| De Vassal, F | 1 |
| Hayat, M | 1 |
| Amiel, JL | 1 |
| Schlumberger, JR | 1 |
| Jasmin, C | 1 |
| Rosenfeld, C | 1 |
| Konior, GS | 1 |
| Yarbro, JW | 1 |
| Stein, KM | 1 |
| Shelley, WB | 1 |
| Weinberg, RA | 1 |
| Lerner, LJ | 1 |
| Bianchi, A | 1 |
| Yiacas, E | 1 |
| Borman, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vinblastine Versus Oral Hydroxiurea in Newly Diagnosed AML With Hyperleukocytosis: a Phase 2 Clinical Study[NCT05062278] | Phase 2 | 46 participants (Anticipated) | Interventional | 2021-07-26 | Recruiting | ||
| A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD[NCT03055247] | Phase 2 | 3 participants (Anticipated) | Interventional | 2015-11-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for hydroxyurea and Leukocytosis
| Article | Year |
|---|---|
Hyperleukocytosis and leukostasis in acute and chronic leukemias.
Topics: Chronic Disease; Humans; Hydroxyurea; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Leukost | 2022 |
Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis.
Topics: Disease-Free Survival; Humans; Hydroxyurea; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; R | 2020 |
The management of hyperleukocytosis in 2017: Do we still need leukapheresis?
Topics: Acute Disease; Female; Humans; Hydroxyurea; Induction Chemotherapy; Leukapheresis; Leukemia; Leukocy | 2018 |
How we approach a patient with symptoms of leukostasis requiring emergent leukocytapheresis.
Topics: Antisickling Agents; Disseminated Intravascular Coagulation; Humans; Hydroxyurea; Leukapheresis; Leu | 2015 |
Hyperleukocytosis, leukostasis and leukapheresis: practice management.
Topics: Acute Disease; Humans; Hydroxyurea; Induction Chemotherapy; Leukapheresis; Leukemia; Leukocyte Count | 2012 |
[Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea].
Topics: Antineoplastic Agents; Bone Marrow; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloge | 1998 |
Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia.
Topics: Aged; Basophils; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Leukemia, Myelogenous, Chron | 2002 |
3 trials available for hydroxyurea and Leukocytosis
| Article | Year |
|---|---|
Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.
Topics: Adult; Antigens, CD34; Benzylamines; beta-Thalassemia; Cyclams; Female; Genetic Therapy; Granulocyte | 2012 |
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; | 2003 |
All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Colony-Forming Units Assay; Female; Hematopoietic Stem Cel | 1996 |
31 other studies available for hydroxyurea and Leukocytosis
| Article | Year |
|---|---|
Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis.
Topics: Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukocytosis | 2020 |
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, | 2021 |
Skin nodules in onset of acute myeloid leukemia, a myelomonocytic variant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Delayed Diagnosis; | 2017 |
Dose-related mucositis with hydroxyurea for cytoreduction in acute myeloid leukemia.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leuk | 2019 |
Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hemat | 2018 |
Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.
Topics: Adult; Alleles; Fusion Proteins, bcr-abl; Heterozygote; Humans; Hydroxyurea; Janus Kinase 2; Leukemi | 2013 |
Clinical reasoning: a 69-year-old man with leukocytosis and hemorrhagic brain lesions.
Topics: Aged; Enzyme Inhibitors; Humans; Hydroxyurea; Intracranial Hemorrhages; Leukocytosis; Male | 2014 |
A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Female | 2015 |
Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Female; Ho | 2016 |
The Use of Hydroxyurea and Leukapheresis in Childhood Acute Leukemia With Hyperleukocytosis.
Topics: Acute Disease; Child; Humans; Hydroxyurea; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis | 2016 |
Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.
Topics: Aged; Female; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Neg | 2009 |
A 62-year-old woman with dyspnea, leukocytosis, and diffuse ground-glass opacities.
Topics: Combined Modality Therapy; Diagnosis, Differential; Dyspnea; Female; Hematopoiesis, Extramedullary; | 2010 |
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antisickling Agents; Bone and Bones; Female; Humans; Hydroxy | 2010 |
Blurred vision, epistaxis, and fever in a young man.
Topics: Acute Disease; Adult; Allopurinol; Antimetabolites; Antineoplastic Agents; Epistaxis; Fever; Fluid T | 2002 |
Concurrent mediastinal B cell lymphoma and chronic myeloid leukemia with an unusually favorable response to chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clone Cells; Combined Modal | 2003 |
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
Topics: Benzamides; Biomarkers; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 5; Disease Progression | 2004 |
Visual loss as a first sign of adult-type chronic myeloid leukemia in a child.
Topics: Blindness; Blood Cell Count; Child; Fluorescein Angiography; Hematopoietic Stem Cell Transplantation | 2005 |
Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Case-Control Studies; Child; Eosinophils; Female; Granulocyt | 2007 |
Rare presentation of leucocytosis.
Topics: Adult; Allopurinol; Humans; Hydroxyurea; Leukemia, Neutrophilic, Chronic; Leukocytosis; Male; Progno | 2006 |
t(8;21) prior to acute leukemia.
Topics: Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Female; Humans; Hydroxyurea; Leukemia, Myel | 1993 |
Treatment of acute promyelocytic leukemia with all-trans retinoic acid: successful control of hyperleukocytosis and leukostasis syndrome with leukaphereses and hydroxyurea.
Topics: Administration, Oral; Adult; Female; Humans; Hydroxyurea; Leukapheresis; Leukemia, Promyelocytic, Ac | 1993 |
Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Component | 2002 |
Extreme leucocytosis and prognosis of newly diagnosed patients with acute non-lymphocytic leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hu | 1979 |
Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia.
Topics: Busulfan; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count; Leukocytosis; Mitobronitol; Splen | 1975 |
High proliferation of early hemopoietic progenitors in tumor-bearing mice.
Topics: Anemia; Animals; Bone Marrow; Carcinoma; Cell Division; Hematopoiesis; Hematopoietic Cell Growth Fac | 1992 |
Effect of hydroxyurea on blood viscosity in chronic myelogenous leukemia with hyperleukocytosis.
Topics: Adolescent; Adult; Blood Viscosity; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR | 1991 |
Postoperative pulmonary leukostasis.
Topics: Aged; Allopurinol; Cytarabine; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia, Myelogenous | 1990 |
Hydroxyurea, leucopheresis, and splenectomy in chronic myeloid leukaemia at the problastic phase.
Topics: Adolescent; Adult; Aged; Blood Transfusion; Busulfan; Demecolcine; Female; Humans; Hydroxyurea; Leuk | 1973 |
Hydroxyurea in the treatment of chronic myeloid leukemia.
Topics: DNA; Humans; Hydroxyurea; Leukemia; Leukocytosis; Middle Aged; Splenomegaly | 1971 |
Hydroxyurea in the treatment of pustular psoriasis.
Topics: Administration, Oral; Adolescent; Female; Fever; Humans; Hydroxyurea; Leukocyte Count; Leukocytosis; | 1971 |
Effects of hydroxyurea and related compounds on the blood and marrow of experimental animals.
Topics: Adrenal Glands; Animals; Antineoplastic Agents; Blood Cell Count; Blood Cells; Body Weight; Hydroxyu | 1966 |